Search results
Results from the Health.Zone Content Network
A jury ordered Johnson & Johnson to pay $260 million to an Oregon woman who said she developed a deadly cancer from using the company’s products that contained talc powder.
The FDA approved two biosimilars for Eylea (aflibercept), a drug used to treat age-related macular degeneration, diabetic retinopathy and other eye conditions. Biosimilars Yesafili and Opuviz work ...
History Early years. The company's origins go back to a Massachusetts real estate investment trust organized in 1969 as DMG, Inc. In 1978, DMG, Inc. was reorganized as a Florida corporation and changed its name to Diversified Mortgage Investors, Inc. DMG had been invested in retirement home developments when it was taken over by the Rales, and in 1984, the company adopted the name Danaher and ...
The Food and Drug Administration (FDA) has approved a new drug for treating two conditions that cause vision loss. The drug Vabysmo (faricimab-svoa) treats wet age-related macular degeneration ...
McKesson Corporation is a publicly-traded American company that distributes pharmaceuticals and provides health information technology, medical supplies, and health management tools. The company delivers a third of all pharmaceuticals used in North America and employs over 51,000 employees. With $263.9 billion in 2023 revenue, it is the ninth ...
DMG-PEG 2000. Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). DMG-PEG 2000 is a synthetic lipid formed by the PEGylation of myristoyl diglyceride. It is used to manufacture lipid nanoparticles that are used in mRNA vaccines, [1] and in particular forms part of the drug delivery ...
Dr. Sarah Yim, a director in the FDA’s Center for Drug Evaluation and Research said Aug. 24 in a release that biosimilar products may encourage competition in the drug marketplace and help ...
Both have become among the world's most valuable publicly traded companies due to explosive demand for their weight-loss drugs. For the first quarter, analysts expect Amgen to report earnings of ...